Central European Journal of Medicine

, Volume 2, Issue 1, pp 12–25 | Cite as

Human leukocyte antigen associations in Finnish liver transplantations due to primary sclerosing cholangitis and primary biliary cirrhosis

  • Irma H. Matinlauri
  • Markku M. Nurminen
  • Krister A. Höckerstedt
  • Helena M. Isoniemi
Research Article
  • 26 Downloads

Abstract

A genetic predisposition has been suggested in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). The aim of the study was to evaluate human leukocyte antigen (HLA) frequencies and HLA associations in Finnish PSC and PBC patients. The relative frequencies of HLA-A,-B, and-DR antigens were compared between patients with PSC (n=50), or PBC (n=89), transplanted due to end-stage liver disease, and healthy members in the Finnish bone marrow donor registry (n=10000). Prevalence differences, prevalence ratios and the associated large-sample significance probabilities (2-sided P-values) and 95% confidence intervals were calculated.

We found a strong positive association between PSC and HLA-B8 and-DR3, and a weak positive association between HLA-A1 and PSC. HLA-DR3 also had a weak positive association with PBC, and a weak negative association between HLA-DR5 and PBC was found. In conclusion, HLA-B8, and-DR3 are susceptible for progressive liver disease in PSC, and HLA-DR3 may also be susceptible for disease progression in PBC. HLA-DR5 may be protective against severe PBC.

Keywords

Human leukocyte antigen liver transplantation primary biliary cirrhosis primary sclerosing cholangitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    K.M. Boberg, A. Bergquist, S. Mitchell, A. Pares, F. Rosina and U. Broomé: “Cholangiocarcinoma in primary sclerosing cholangitis: Risk factors and clinical presentation”, Scand J. Gastroenterol., Vol. 37, (2002), pp. 1205–1211.PubMedCrossRefGoogle Scholar
  2. [2]
    B. Brandsaeter, H. Isoniemi, U. Broomé, M. Olausson, L. Bäckman and B. Hansen: “Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy”, J. Hepatol., Vol. 40, (2004), pp. 815–822.PubMedCrossRefGoogle Scholar
  3. [3]
    K. Bjoro and E. Schrumpf: “Liver transplantation for primary sclerosing cholangitis”, J. Hepatol., Vol. 40, (2004), pp. 570–577.PubMedCrossRefGoogle Scholar
  4. [4]
    U. Broomé, H. Glaumann, R. Hultcrantz and U. Forsum: “Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis”, Scand J. Gastroenterol, Vol. 25, (1990), pp. 54–58.PubMedGoogle Scholar
  5. [5]
    A. Bergquist, G. Lindberg, S. Saarinen and U. Broomé: “Increased prevalence of primary sclerosing cholangitis among first-degree relatives”, J. Hepatol., Vol. 42, (2005), pp. 252–256.PubMedCrossRefGoogle Scholar
  6. [6]
    C. Selmi, P. Invernizzi, M. Zuin, M. Podda, M.F. Seldin and M.E. Gershwin: “Genes and (auto)immunity in primary biliary cirrhosis”, Genes Immun., Vol. 6, (2005), pp. 543–556.PubMedCrossRefGoogle Scholar
  7. [7]
    J.J. Feld and E.J. Heathcote: “Epidemiology of autoimmune liver disease”, J Gastroenterol. Hepatol., Vol. 18, (2003), pp. 1118–1128.PubMedCrossRefGoogle Scholar
  8. [8]
    C. Barbatis, P. Kelly, J. Greveson, A. Heryet and J. McGee: “Immunocytochemical analysis of HLA class II (DR) antigens in liver disease in man”, J. Clin. Pathol., Vol. 40, (1987), pp. 879–884.PubMedGoogle Scholar
  9. [9]
    R.W. Chapman, Z. Varghese, R. Gaul, G. Patel, N. Kokinon and S. Sherlock: “Association of primary sclerosing cholangitis with HLA-B8”, Gut, Vol. 24, (1983), pp. 38–41.PubMedGoogle Scholar
  10. [10]
    O. Olerup, R. Olsson, R. Hultcrantz and U. Broome: “HLA-DR and HLA-DQ are not markers for rapid disease progression in primary sclerosing cholangitis”, Gastroenterology, Vol. 108, (1995), pp. 870–878.PubMedCrossRefGoogle Scholar
  11. [11]
    A. Spurkland, S. Saarinen, K.M. Boberg, S. Mitchell, U. Broome and L. Caballeria: “HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations”, Tissue Antigens, Vol. 53, (1999), pp. 459–469.PubMedCrossRefGoogle Scholar
  12. [12]
    S. Saarinen, O. Olerup and U. Broomé: “Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis”, Am. J. Gastroenterol., Vol. 95, (2000), pp. 3195–3199.PubMedCrossRefGoogle Scholar
  13. [13]
    J.M. Farrant, D.G. Doherty, P.T. Donaldson, R.W. Vaughan, K.M. Hayllar and K.I. Welsh: “Amino acid substitutions at position 38 of the DRβ polypeptide confer susceptibility to and protection from primary sclerosing cholangitis”, Hepatology, Vol. 16, (1992), pp. 390–395.PubMedGoogle Scholar
  14. [14]
    W.Z. Mehal, Y.-M.D. Lo, B.P. Wordsworth, J.M. Neuberger, S.C. Hubscher, K.A. Fleming and R.W. Chapman: “HLA DR4 is a marker for rapid disease progression in primary sclerosing cholangitis”, Gastroenterology, Vol. 106, (1994), pp. 160–167.PubMedGoogle Scholar
  15. [15]
    K.M. Boberg, A. Spurkland, G. Rocca, T. Egeland, S. Saarinen and S. Mitchell: “The HLA-DR3,DQ2 heterozygous genotype is associated with an accelerated progression of primary sclerosing cholangitis”, Scand. J. Gastroenterol., Vol. 36, (2001), pp. 886–890.PubMedCrossRefGoogle Scholar
  16. [16]
    G.J. Gores, S.B. Moore, L.D. Fisher, F.C. Powell and E.R. Dickson: “Primary biliary cirrhosis: associations with class II major histocompatibility complex antigens”, Hepatology, Vol. 7, (1987), pp. 889–892.PubMedGoogle Scholar
  17. [17]
    D.E. Johnston, M.M. Kaplan, K.B. Miller, C.M. Connors and E.L. Milford: “Histo-compatibility antigens in primary biliary cirrhosis”, Am. J. Gastroenterol., Vol. 82, (1987), pp. 1127–1129.PubMedGoogle Scholar
  18. [18]
    M.P. Manns, A. Bremm, P.M. Schneider, A. Notghi, G. Gerken and M. Prager-Eberle: “HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis”, Gastroenterology, Vol. 101, (1991), pp. 1367–1373.PubMedGoogle Scholar
  19. [19]
    J. Underhill, P. Donaldson, G. Bray, D. Doherty, B. Portmann and R. Williams: “Susceptibility to primary biliary cirrhosis is associated with the HLA-DR8-DQB1*0402 haplotype”, Hepatology, Vol. 16, (1992), pp. 1404–1408.PubMedGoogle Scholar
  20. [20]
    N. Morling, K. Dalhoff, L. Fugger, J. Georgsen, B. Jakobsen and L. Ranek: “DNA polymorphism of HLA calss II genes in primary biliary cirrhosis”, Immunogenetics, Vol. 35, (1992), pp. 112–116.PubMedGoogle Scholar
  21. [21]
    W.L. Gregory, W. Mehal, A.N. Dunn, G. Cavanagh, R. Chapman and K.A. Fleming: “Primary biliary cirrhosis: contribution of HLA class II allele DR8”, QJM-Int. J. Med., Vol. 86, (1993), pp. 393–399.Google Scholar
  22. [22]
    A.B. Begovich, W. Klitz, P.V. Moonsamy, J. Van de Water, G. Peltz and M.E. Gershwin: “Genes within the HLA class II region confer both predisposition and resistance to primary biliary cirrhosis”, Tissue Antigens, Vol. 43, (1994), pp. 71–77.PubMedGoogle Scholar
  23. [23]
    G. Ercilla, A. Parés, F. Arriaga, M. Bruguera, R. Castillo, J. Rodés and J. Vives: “Primary biliary cirrhosis associated with HLA-Drw3”, Tissue Antigens, Vol. 14, (1979), pp. 449–452.PubMedCrossRefGoogle Scholar
  24. [24]
    B. Brandsaeter, S. Friman, U. Broome, H. Isoniemi, M. Olausson and L. Bäckman: “Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic Countries”, Scand. J. Gastroenterol., Vol. 38, (2003), 1176–1183.PubMedCrossRefGoogle Scholar
  25. [25]
    M.K. Sirén, H. Sareneva, M.L. Lokki and S. Koskimies: “Unique HLA antigen frequencies in the Finnish population”, Tissue Antigens, Vol. 48, (1996), pp. 703–707.PubMedCrossRefGoogle Scholar
  26. [26]
    O. Miettinen and M. Nurminen: “Comparative analysis of two rates”, Stat. Med., Vol. 4, (1985), pp. 213–226.PubMedGoogle Scholar
  27. [27]
    StatXact 5, Statistical software for exact nonparametric inference, CYTEL Software Corporation, Cambridge, MA, 2001.Google Scholar
  28. [28]
    S. Wacholder, S. Chanock, M. Garcia-Closas, L. El ghormli and N. Rothman: “Assessing the probability of false positive reports in molecular epidemiology studies”, J. Nat. Cancer Inst., Vol. 96, (2004), pp. 424–442. Website for calculating the probability: http://jncicancerspectrum.oxfordjournals.org/content/vol96/issue6/images/data/434/DC1/Wacholder_FPRP_prototype_spreadsheet_040227.xls CrossRefGoogle Scholar
  29. [29]
    K. Wiencke, A. Spurkland, E. Schrumpf and K.M. Boberg: “Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles”, Hepatology, Vol. 34, (2001), pp. 625–630.PubMedGoogle Scholar
  30. [30]
    H. Zetterquist, U. Broome, K. Einarsson and O. Olerup: “HLA class II genes in primary sclerosing cholangitis and chronic inflammatory bowel disease: no HLA-DRw52a association in Swedish patients with sclerosing cholangitis”, Gut, Vol. 33, (1992), pp. 942–946.PubMedGoogle Scholar
  31. [31]
    E. Schrumpf, O. Fausa, O. Forre, J.H. Dobloug, S. Ritland and E. Thorsby: “HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease”, Scand. J. Gastroenterol., Vol. 17, (1982), pp. 187–191.PubMedCrossRefGoogle Scholar
  32. [32]
    P.T. Donaldson, D.G. Doherty, K.M. Hayllar, I.G. McFarlane, P.J. Johnson, R. Williams: “Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors”, Hepatology, Vol. 13, (1991), pp 701–706.PubMedCrossRefGoogle Scholar
  33. [33]
    M.D.J. Strettell, P.T. Donaldson, L.J. Thomson, P.J. Santrach, S.B. Moore, A.J. Czaja and R. Williams: “Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis”, Gastroenterology, Vol. 112, (1997), pp. 2028–2035.PubMedCrossRefGoogle Scholar
  34. [34]
    A. Davidson and B. Diamond: “Advances in Immunology, Autoimmune diseases”, N. Engl. J. Med., Vol. 345, (2001), pp. 340–350.PubMedCrossRefGoogle Scholar

Copyright information

© Versita Warsaw and Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • Irma H. Matinlauri
    • 1
  • Markku M. Nurminen
    • 2
  • Krister A. Höckerstedt
    • 3
  • Helena M. Isoniemi
  1. 1.Department of Clinical Chemistry, Laboratory CenterKuopio University Hospital and Kuopio UniversityKuopioFinland
  2. 2.Department of Public HealthUniversity of Helsinki, and Finnish Institute of Occupational HealthHelsinkiFinland
  3. 3.Transplantation and Liver Surgery Clinic, Department of SurgeryHelsinki University HospitalHelsinkiFinland

Personalised recommendations